A 30-year-old female presented with rapid onset of acute dysarthria and left oculomotor paralysis. The MRI showed ruptured anterior midbrain cavernoma. A conservative approach was adopted as the patient was stable. However, one month later she experienced a new bleed with right hemiparesis, diplopia and severe dysarthria. The haemorrhage extended to the surface of the midbrain anteriorly and extended posteriorly without reaching the surface of the safe entry zone. The approach to a cavernous malformation via safe zones are not always feasible due to the proximity of several critical neural structures as in this case. The resection via a posterolateral route using the supracerebellar infratentorial approach was performed successfully.
As many as half of patients diagnosed with metastatic HER2-positive breast cancer will see their cancer spread to their brain. Though brain metastases, or "Brain Mets," are rare, they are exceedingly difficult to treat, so these patients experience poor outcomes. At this year’s ASCO meeting, Dr. Nancy Lin of Dana-Farber Cancer Institute presented promising results from the HER2CLIMB trial for these patients. In this video BCRF talks with Dr. Lin about her research focus, Brain Mets, and HER2CLIMB’s findings.
Watch Dr. Jamie Studts discuss the quality implementation of lung cancer screening and share his thoughts on optimizing community-based implementation.
This is a recording of the American Lung Association’s Lung Cancer Precision Medicine Summit which took place on June 18, 2020. Oncologists Dr. Erin Schenk and Dr. Ibiayi Dagogo-Jack discuss which precision medicine treatment is available for lung cancer patients and promising new research. Carly Ornstein, National Director of Lung Cancer Education, gives a high-level overview of precision medicine and discusses new resources.
Dr. Pasi Janne, Director of Dana-Farber Cancer Institute’s Lowe Center for Thoracic Oncology and Belfer Center for Applied Cancer Science, and colleagues discuss how COVID-19 is changing the screening, management, and treatment of thoracic cancer, including:
- The impact on lung cancer screening
- The role of telemedicine in caring for cancer patients
- Managing clinical trials
Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients. An international team of researchers based this conclusion on a retrospective analysis of data from a large clinical trial.
This lively debate covers the pros and cons involved with endoscopic vs surgical resection, followed by a summary and discussion including recent advances and research on the topic.
Watch Dr. Sarah McLaughlin, M.D., a surgical oncologist, discuss her strategies for effective breast cancer treatment. When we think about breast cancer treatment, we think about it from a comprehensive strategy of the breast, of what could be going on elsewhere in the body, and then how do we as physicians create a treatment plan that addresses all of those issues. The future of breast cancer care is getting more and more targeted. The more targeted, the better the outcomes and the fewer the side effects.
Greg Durm, MD, a medical oncologist, and researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, describes how researchers are testing if giving an immunotherapy drug called pembrolizumab following surgery is better than observation following surgery in adults with this type of cancer.
Watch this video of the surgical removal of a brain tumor that originated from the lung. The tumor had resulted in obstructive hydrocephalus. Case presentation by Dr. Farhad Limonadi MD, director of neurosurgery at Eisenhower Medical Center.